BG104940A - Пароксетин аскорбат - Google Patents

Пароксетин аскорбат Download PDF

Info

Publication number
BG104940A
BG104940A BG104940A BG10494000A BG104940A BG 104940 A BG104940 A BG 104940A BG 104940 A BG104940 A BG 104940A BG 10494000 A BG10494000 A BG 10494000A BG 104940 A BG104940 A BG 104940A
Authority
BG
Bulgaria
Prior art keywords
paroxetine
ascorbate
salt
paroxetine ascorbate
solution
Prior art date
Application number
BG104940A
Other languages
Bulgarian (bg)
English (en)
Inventor
Michael Urquhart
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of BG104940A publication Critical patent/BG104940A/bg

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BG104940A 1998-04-25 2000-11-13 Пароксетин аскорбат BG104940A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9808896.6A GB9808896D0 (en) 1998-04-25 1998-04-25 Novel compound
PCT/GB1999/001244 WO1999055698A1 (en) 1998-04-25 1999-04-23 Paroxetine ascorbate

Publications (1)

Publication Number Publication Date
BG104940A true BG104940A (bg) 2001-09-28

Family

ID=10831008

Family Applications (1)

Application Number Title Priority Date Filing Date
BG104940A BG104940A (bg) 1998-04-25 2000-11-13 Пароксетин аскорбат

Country Status (20)

Country Link
EP (1) EP1089995A1 (zh)
JP (1) JP2002513019A (zh)
KR (1) KR20010042977A (zh)
CN (1) CN1297448A (zh)
AP (1) AP2000001963A0 (zh)
AU (1) AU3618499A (zh)
BG (1) BG104940A (zh)
BR (1) BR9909868A (zh)
CA (1) CA2330055A1 (zh)
EA (1) EA200001104A1 (zh)
GB (1) GB9808896D0 (zh)
HU (1) HUP0102116A3 (zh)
ID (2) ID26654A (zh)
IL (1) IL139081A0 (zh)
NO (1) NO20005352D0 (zh)
PL (1) PL343677A1 (zh)
SK (1) SK15912000A3 (zh)
TR (1) TR200003084T2 (zh)
WO (1) WO1999055698A1 (zh)
ZA (1) ZA200005912B (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
IL159280A0 (en) * 2001-06-14 2004-06-01 Teva Pharma A process for preparing paroxetine hcl which limits formation of pink colored compounds
CA2471144C (en) 2002-01-09 2011-06-07 Emisphere Technologies, Inc. Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoate
CN110607553B (zh) * 2018-10-30 2024-03-22 中国科学院化学研究所 一种制备粒径可调的药物或药物中间体单晶或无定型物的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
ES2058061T3 (es) * 1985-10-25 1994-11-01 Beecham Group Plc Derivado de piperidina, su preparacion y su uso como medicamento.
US5276042A (en) * 1993-04-16 1994-01-04 Crenshaw Roger T Treatment of premature ejaculation
ES2117557B1 (es) * 1996-02-29 1999-07-01 Ferrer Int Nuevo procedimiento de obtencion de (-)-trans -n-p-fluorobenzoilmetil-4-(p-fluorofenil)-3- ((3,4-(metilendioxi)fenoxi ) metil)-piperidina.

Also Published As

Publication number Publication date
WO1999055698A1 (en) 1999-11-04
HUP0102116A3 (en) 2002-12-28
PL343677A1 (en) 2001-08-27
SK15912000A3 (sk) 2001-04-09
GB9808896D0 (en) 1998-06-24
JP2002513019A (ja) 2002-05-08
EA200001104A1 (ru) 2001-04-23
EP1089995A1 (en) 2001-04-11
IL139081A0 (en) 2001-11-25
ID26083A (id) 2000-11-23
HUP0102116A2 (hu) 2002-05-29
ZA200005912B (en) 2001-12-19
TR200003084T2 (tr) 2001-02-21
CN1297448A (zh) 2001-05-30
NO20005352L (no) 2000-10-24
AU3618499A (en) 1999-11-16
NO20005352D0 (no) 2000-10-24
BR9909868A (pt) 2000-12-19
KR20010042977A (ko) 2001-05-25
AP2000001963A0 (en) 2000-12-31
CA2330055A1 (en) 1999-11-04
ID26654A (id) 2001-01-25

Similar Documents

Publication Publication Date Title
US20040242506A1 (en) Paroxetine glycyrrhizinate
US6110940A (en) Salts of an anti-migraine indole derivative
JP5168711B2 (ja) ソリフェナシンまたはその塩の固形製剤用組成物
JP2007532548A (ja) バゼドキシフェンアセテートの結晶質多形体
KR20060135866A (ko) 바제독시펜 아세테이트의 결정질 다형체
WO1999040084A1 (en) Salts of paroxetine
BG104940A (bg) Пароксетин аскорбат
CA2327450A1 (en) Paroxetine maleate
CA2329913A1 (en) Paroxetine 10-camphorsulfonate for treatment of cns disorders
MXPA00010439A (en) Paroxetine ascorbate
CZ20003942A3 (cs) Askorbat paroxetinu
MXPA00010435A (en) Paroxetine 10-camphorsulfonate for treatment of cns disorders
US20030028027A1 (en) Paroxetine maleate
AU2528899A (en) Salts of paroxetine
CZ20003941A3 (cs) 10-KafrsuIfonat paroxetinu pro léčbu poruch centrálního nervového systému
MXPA00009884A (en) Paroxetine maleate
CZ20003722A3 (cs) Maleat paroxetinu
MXPA00007719A (en) Salts of paroxetine
WO2001025230A1 (en) Process for the preparation of paroxetine hydrochloride acetone solvate
WO2001014369A2 (en) Process for the preparation of paroxetin.hcl
CZ20002845A3 (cs) Soli paroxetinu
WO2001025231A1 (en) Process for the preparation of paroxetine hydrochloride acetone solvate